A non-industry-funded RCT conducted by The Diabetic Retinopathy Clinical Research Network (DRCR.net) found similar risks of any Antiplatelet Trialists’ Collaboration Event (i.e. non-fatal MI, non-fatal stroke, or vascular death) after adjusting for age, sex, hemoglobin A1c level at the baseline, diabetes type and time since diagnosis at the baseline, insulin use, prior coronary artery disease (CAD), prior MI, prior stroke, prior TIA, prior HT, and smoking status among DME patients treated with aflibercept (5%), bevacizumab (8%), and ranibizumab (12%) [49]. This evidence concerns the gene INS and diabetes mellitus.